These are the experimental results of STARR FLUC, which differ from the graph of LUC-samRNA in the Japan presentation document you attached in your post.
In the graph of LUC-samRNA, the luciferase luminescence is almost zero on day 15, which is extremely unnatural. It looks as if a straight line has been drawn by hand.
The graph of LUC-samRNA is also included in the KOSTAIVE drug approval materials (see P.59).
Placental transfer of Kostaive was discussed based on the results of the fertility studies, embryo-fetal studies, and developmental toxicity studies on ARCT-021 (CTD 4.2.3.5.3-01). mRNA-2002 was undetectable in placenta or fetal tissues in any treatment group studied, except in the plasma (8.19 pg/mL) of a fetus in 1 of 20 samples in the 10 ug group. ATX-126 was detectable in placenta in the 10 and 20 ug groups (275.0 ± 33.9 ng/g in the 10 ug group, 387.6 ± 117.8 ng/g in the 20 ug group), but not detected in plasma or tissues of fetuses in either of the groups. The above results suggest that ARCT-021 is unlikely to be transferred from maternal animals to fetuses. The same is considered to apply to Kostaive.
Note:
mRNA-2002: nsP1-nsP4 (VEEV) + full length Spike (Wuhan)
A little more about the Ingredients in Kostaive which means REVENGE in Finnish
https://geoffpain.substack.com/p/arcturus-therapeutics-jab-endotoxin
Please check FIGs.18A to 18C of US20210290756A1.
https://patentimages.storage.googleapis.com/66/d2/e6/23a4a3e40e0bbb/US20210290756A1.pdf
These are the experimental results of STARR FLUC, which differ from the graph of LUC-samRNA in the Japan presentation document you attached in your post.
In the graph of LUC-samRNA, the luciferase luminescence is almost zero on day 15, which is extremely unnatural. It looks as if a straight line has been drawn by hand.
The graph of LUC-samRNA is also included in the KOSTAIVE drug approval materials (see P.59).
https://www.pmda.go.jp/files/000269813.pdf
KOSTAIVE drug approval materials (see P.21).
https://www.pmda.go.jp/files/000269813.pdf
Placental transfer of Kostaive was discussed based on the results of the fertility studies, embryo-fetal studies, and developmental toxicity studies on ARCT-021 (CTD 4.2.3.5.3-01). mRNA-2002 was undetectable in placenta or fetal tissues in any treatment group studied, except in the plasma (8.19 pg/mL) of a fetus in 1 of 20 samples in the 10 ug group. ATX-126 was detectable in placenta in the 10 and 20 ug groups (275.0 ± 33.9 ng/g in the 10 ug group, 387.6 ± 117.8 ng/g in the 20 ug group), but not detected in plasma or tissues of fetuses in either of the groups. The above results suggest that ARCT-021 is unlikely to be transferred from maternal animals to fetuses. The same is considered to apply to Kostaive.
Note:
mRNA-2002: nsP1-nsP4 (VEEV) + full length Spike (Wuhan)
ATX-126: Component of LNP
Thanks very much.